AstraZeneca abandons Vaxzevria for commercial reasons—sorry, it's not that simple—there's a supply chain to consider
Materials and components will still be located all over the globe; some hazardous!
AstraZeneca abandons Vaxzevria for commercial reasons
Below is an announcement from the European Commission on AstraZeneca’s withdrawal of its SARS-CoV-2 sterile injectable ‘Vaxzevria’:
Vaxzevria1 (COVID 19 Vaccine (ChAdOx1 S [recombinant])): Withdrawal of the marketing authorisation in the European Union
It begins: “On 27 March 2024, the European Commission withdrew the marketing authorisation for Vaxzevria (COVID 19 Vaccine (ChAdOx1 S [recombinant])) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.”
Sorry, but it’s not that simple
Unfortunately, it is not that simple. A fully functioning supply chain was constructed for the development, manufacture and distribution of Vaxzevria sterile injectables.
MHRAs own Rules and Guidance for Pharmaceutical Manufacturers and Distributors (The MHRA Ora…